Skip to main content

Efficacy and safety of current interventions for high myopia control in children: a systematic review and network meta-analysis

In brief

Red-light therapy reduced eye growth by an estimated 0.43 mm versus control

In a review of 28 studies involving 2,202 children and adolescents with high myopia, repeated low-level red-light therapy showed the largest estimated one-year reductions in eye elongation and refractive progression versus control. Orthokeratology, rigid gas-permeable lenses, and posterior scleral reinforcement also showed benefits; most evidence was non-randomized, so head-to-head trials and longer-term safety data are still needed.

Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Li Li, Kunhong Xiao, Haoqiang Cui, Wenyi Hu, Wei Wang, Xiaohu Ding, et al.
PMID
43049921
DOI
10.1007/s00417-026-07612-7

Why clinicians should know about it

  • Picked for Ophthalmology (paper of the day, 19 November 2026): Pediatric high-myopia control directly informs clinical management

Abstract

BACKGROUND: High myopia in children and adolescents is a growing public health concern associated with increased risk of irreversible vision impairment. Identifying the most effective and safe intervention to slow its progression is critical. METHODS: We searched PubMed, EMBASE, Scopus, Cochrane Library, ClinicalTrials.gov, and WHO ICTRP for randomized controlled trials and observational studies (NOS score ≥ 6 or low/moderate ROBINS-I bias risk) published until March 16, 2025. Twelve interventions were evaluated. PRIMARY OUTCOMES: annual change in refractive error (D/year) and axial length (mm/year). SECONDARY OUTCOMES: adverse events. Random-effects pairwise and network meta-analyses were performed. Inconsistency (node-splitting) and sensitivity analyses (restricting follow-up duration, heterogeneity, and high myopia definition [ ≤ - 6.00D]) assessed robustness. RESULTS: Twenty-eight studies (2,885 eyes; 2,202 participants) were included. Repeated Low-level Red Light (RLRL) showed the greatest reduction in axial elongation (-0.43 mm; 95% CI, - 0.51 to - 0.36) and refractive progression (+ 0.95 D; +0.68 to + 1.22) versus control. Rigid gas permeable lenses (RGP: - 0.13 mm [-0.21 to - 0.05]; +0.83 D [+ 0.52 to + 1.14]), orthokeratology (-0.19 mm [-0.26 to - 0.12]; +0.36 D [+ 0.14 to + 0.58]), and posterior scleral reinforcement (PSR: - 0.18 mm [-0.24 to - 0.13]; +0.55 D [+ 0.38 to + 0.73]) were also effective. Multifocal soft contact lenses modestly improved refraction (+ 0.42 D [+ 0.05 to + 0.78]) but not axial length (-0.11 mm [-0.24 to + 0.02]). Atropine 0.01% and DIMS lenses did not significantly affect refraction. RLRL ranked highest (SUCRA: 95.0% axial length; 89.6% refraction). Results were consistent in sensitivity analyses. Adverse events were mild, with no sight-threatening complications. CONCLUSIONS: RLRL showed the largest estimated effects and ranked highest among the evaluated interventions for one-year control of pediatric high myopia, while PSR, RGP, and orthokeratology also showed potential benefits. These comparative findings should be interpreted cautiously given the predominance of non-randomized evidence, and further head-to-head RCTs are needed to confirm the relative efficacy and long-term safety of these interventions. KEY MESSAGES: WHAT IS KNOWN : Evidence for myopia-control interventions is well established in children with low-to-moderate myopia, but comparative evidence specifically for pediatric high myopia remains limited. WHAT IS NEW: This systematic review and network meta-analysis compares 12 single and combined interventions for pediatric high myopia across 28 studies. Repeated low-level red-light therapy showed the largest estimated effects and ranked highest for both refractive and axial-length control, while posterior scleral reinforcement, rigid gas-permeable lenses, and orthokeratology also showed potential benefits. Evidence for 0.01% atropine and DIMS lenses was limited, and the comparative estimates should be interpreted cautiously because most included studies were non-randomized.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.